Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism

NCT07197450 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Hypoparathyroidism

Interventions

DRUG: intravenous administration of PTH1-84 mRNA

Sponsor

Peking Union Medical College Hospital